Orphazyme Investor Relations Material
Latest events
H1 2021
Orphazyme
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Orphazyme
Access all reports
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company's lead drug candidate is epoprostenol sodium and its analogues, Phase III ready lipidic compounds, which are being developed as an innovative treatment option targeting the underlying cause of these diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇩🇰 Denmark